{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T20:33:24Z","timestamp":1654634004126},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,21]],"date-time":"2010-02-21T00:00:00Z","timestamp":1266710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00393-009-0600-x","type":"journal-article","created":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T09:08:12Z","timestamp":1266570492000},"page":"561-567","source":"Crossref","is-referenced-by-count":10,"title":["Aktualisierte Stellungnahme der GKJR zur Meldung der FDA \u00fcber F\u00e4lle von Malignomen bei Anti-TNF-behandelten Patienten vom 04.08.2009"],"prefix":"10.1007","volume":"69","author":[{"given":"G.","family":"Horneff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hospach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dannecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"F\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Girschick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.I.","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Keitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Trauzeddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,21]]},"reference":[{"key":"600_CR1","unstructured":"Amgen (2009) Amgen and Wyeth statement on FDA announcement about tumor necrosis factor (TNF) blockers. http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2009&releaseID=1316767"},{"key":"600_CR2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","volume":"64","author":"Askling","year":"2005","unstructured":"Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414\u20131420","journal-title":"Ann Rheum Dis"},{"key":"600_CR3","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","volume":"60","author":"Askling","year":"2009","unstructured":"Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180\u20133189","journal-title":"Arthritis Rheum"},{"key":"600_CR4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692\u2013701","journal-title":"Arthritis Rheum"},{"key":"600_CR5","unstructured":"Batzler WU, Giersiepen K, Hentschel S et al (2008) Cancer in Germany 2003\u20132004. Incidence and trends. In: Katalinic A, Bertz J, Haberland J, Wolf U (Hrsg) 6, 1\u2013113. 2008. Berlin, Robert-Koch-Institut, Berlin, und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. http:\/\/www.ekr.med.uni-erlangen.de\/GEKID\/Doc\/kid2008_english.pdf"},{"key":"600_CR6","unstructured":"Bernatsky S, Rosenberg A, Oen KG et al (2009) Malignancy in juvenile idiopathic arthritis. Arthritis Rheum 60(Suppl), Abstract 250"},{"key":"600_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0b013e31818cf555","volume":"48","author":"Cucchiara","year":"2009","unstructured":"Cucchiara S, Escher JC, Hildebrand H et al (2009) Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 48:257\u2013267","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"600_CR8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","volume":"65","author":"Franklin","year":"2006","unstructured":"Franklin J, Lunt M, Bunn D et al (2006) Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65:617\u2013622","journal-title":"Ann Rheum Dis"},{"key":"600_CR9","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794\u20132804","journal-title":"Arthritis Rheum"},{"key":"600_CR10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0028-1086037","volume":"220","author":"Guellac","year":"2008","unstructured":"Guellac N, Niehues T (2008) Interdisziplin\u00e4re S2-Leitlinie der juvenilen idiopathischen Arthritis. Klin P\u00e4diatr 220:392\u2013402","journal-title":"Klin P\u00e4diatr"},{"key":"600_CR11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00393-005-0002-7","volume":"65","author":"Horneff","year":"2006","unstructured":"Horneff G (2006) Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Konsensus-Statement des 7. W\u00f6rlitzer Expertengespr\u00e4ches 2004 f\u00fcr die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Z Rheumatol 65:152\u2013158","journal-title":"Z Rheumatol"},{"key":"600_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519\u2013525","journal-title":"Ann Rheum Dis"},{"key":"600_CR13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638\u20131644","journal-title":"Ann Rheum Dis"},{"key":"600_CR14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00393-008-0426-y","volume":"68","author":"Hospach","year":"2009","unstructured":"Hospach T, Haas JP, Huppertz HI et al (2009) Stellungnahme der Gesellschaft f\u00fcr Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) \u00fcber F\u00e4lle von Malignomen bei Anti-TNF-behandelten Patienten. Z Rheumatol 68:162\u2013164","journal-title":"Z Rheumatol"},{"key":"600_CR15","unstructured":"Kaatsch P, Spix C (2009) Deutsches Kinderkrebsregister. Jahresbericht 2008. Institut f\u00fcr Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Obere Zahlbacher Strasse 69, 55131 Mainz. http:\/\/www.kinderkrebsregister.de"},{"key":"600_CR16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2005.02.004","volume":"56","author":"Kwon","year":"2005","unstructured":"Kwon JH, Farrell RJ (2005) The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 56:169\u2013178","journal-title":"Crit Rev Oncol Hematol"},{"key":"600_CR17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPG.0b013e3181957a11","volume":"48","author":"Mackey","year":"2009","unstructured":"Mackey AC, Green L, Leptak C et al (2009) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 48:386\u2013388","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"600_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","volume":"44","author":"Mackey","year":"2007","unstructured":"Mackey AC, Green L, Liang LC et al (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:265\u2013267","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"600_CR19","unstructured":"Minden K (2008) Prognose der rheumatischen Erkrankungen im Kindes- und Jugendalter. Kinder- und Jugendarzt 4:258\u2013266"},{"key":"600_CR20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/1042819021000035662","volume":"44","author":"Navarro","year":"2003","unstructured":"Navarro JT, Ribera JM, Mate JL et al (2003) Hepatosplenic T-gammadelta lymphoma in a patient with Crohn\u2019s disease treated with azathioprine. Leuk Lymphoma 44:531\u2013533","journal-title":"Leuk Lymphoma"},{"key":"600_CR21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"Rosh","year":"2007","unstructured":"Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn\u2019s disease: a cautionary tale? Inflamm Bowel Dis 13:1024\u20131030","journal-title":"Inflamm Bowel Dis"},{"key":"600_CR22","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","volume":"14","author":"Salloum","year":"1996","unstructured":"Salloum E, Cooper DL, Howe G et al (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14:1943\u20131949","journal-title":"J Clin Oncol"},{"key":"600_CR23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","volume":"88","author":"Thomas","year":"2000","unstructured":"Thomas E, Brewster DH, Black RJ et al (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497\u2013502","journal-title":"Int J Cancer"},{"key":"600_CR24","unstructured":"U.S. Food and Drug Administration (2008) Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). http:\/\/www.fda.gov\/cder\/drug\/early_comm\/TNF_blockers.htm"},{"key":"600_CR25","unstructured":"U.S. Food and Drug Administration (2009) Follow-up to the june 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174449.htm"},{"key":"600_CR26","unstructured":"U.S. Food and Drug Administration (2009) Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174474.htm"},{"key":"600_CR27","unstructured":"U.S. Food and Drug Administration (2009) Questions and answers \u2013 TNF blockers 8\/25\/2009. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm180694.htm"},{"key":"600_CR28","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740\u20131751","journal-title":"Arthritis Rheum"},{"key":"600_CR29","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886\u20132895","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0600-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0600-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:01Z","timestamp":1559046961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0600-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,21]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0600-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,21]]}}}